Transdermal Apixaban Delivery Sustaining Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Direct oral anticoagulants (DOACs) experience peak and valley pharmacokinetic behavior with standard immediate-release oral delivery, leading to toxicity and side effects such as bleeding complications, and current administration methods fail to bypass the gastrointestinal system, which contributes to gastrointestinal bleeding risks.
Innovation Solution
Transdermal, intramuscular, and subcutaneous delivery systems are employed to provide continuous, sustained release of DOACs, bypassing the gastrointestinal system and reducing dosing frequency, thereby minimizing peak blood levels and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standard immediate-release oral delivery is used, then drug administration is simple and convenient, but peak and valley pharmacokinetic behavior occurs leading to toxicity and side effects
Solution Approach 1:
The patent changes the pharmacokinetic parameters by switching from immediate-release to sustained-release formulations, and from oral to transdermal delivery routes. This transforms the drug release profile from pulsatile (peak-valley) to continuous, eliminating the harmful pharmacokinetic behavior while maintaining ease of use through patch application
Solution Approach 2:
The transdermal delivery system provides continuous drug release through the skin, maintaining steady therapeutic levels without the intermittent peak-valley pattern of oral dosing. The sustained-release mechanism ensures continuous action while bypassing gastrointestinal absorption issues
2Loss of time
If oral administration is used, then dosing frequency can be reduced, but gastrointestinal bleeding risks increase due to failure to bypass the gastrointestinal system
Solution Approach 1:
The patent extracts the drug delivery route from the gastrointestinal system and relocates it to the transdermal route. By taking out the oral administration pathway and replacing it with skin delivery, the system eliminates gastrointestinal exposure while maintaining effective drug delivery and reducing dosing frequency
3Object-affected harmful factors
If continuous delivery is used, then peak blood levels are minimized reducing adverse effects, but device complexity increases
Solution Approach 1:
The patent changes the delivery parameters by implementing sustained-release mechanisms within the transdermal patch, controlling drug release kinetics to maintain steady levels. This pharmacokinetic parameter modification reduces adverse effects without requiring complex external control systems
Solution Approach 2:
The transdermal patch is designed as a self-regulating system where the drug release is controlled by the patch structure itself (matrix or reservoir design), eliminating the need for external pumps or complex control mechanisms. The system self-regulates delivery through passive diffusion and sustained-release properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These delivery methods reduce the frequency of dosing, lower drug exposure, and minimize adverse effects associated with peak plasma concentrations, potentially eliminating gastrointestinal bleeding risks and improving treatment outcomes by maintaining therapeutic effects with lower drug doses.
Implementation Method 1
Transdermal, intramuscular, and subcutaneous delivery systems are employed to provide continuous, sustained release of DOACs
Implementation Method 2
provide continuous, sustained release of DOACs, bypassing the gastrointestinal system and reducing dosing frequency, thereby minimizing peak blood levels and adverse effects
Data Source
AI summary
Continuous drug delivery systems for apixaban and other direct oral anticoagulants (DOACs).